Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway

Table 3

Biometric results, plasma and urinary analyses, and pretreatment and posttreatment.

	C	CE	HF	HFE
Pretreatment
Body mass (g)		—	^a	—
Food intake (g)		—	^a	—
Water intake (mL)		—	^a
OGTT (a.u.c)		—	^a	—
Posttreatment
Body mass (g)			^a	^b
Food intake (g)			^a	^b
Water intake (mL)		^a	^a	^b
OGTT (a.u.c)			^a	^b
Plasma parameters
HOMA-IR			^a	^b
Fasting glucose (mmol/L)			^a	^b
Plasma insulin (microU/L)			^a	^b
Plasma cholesterol (mg/dL)			^a	^b
Plasma uric acid (mg/dL)		^a	^a	^b
Urinary parameters
Urinary volume (mL/24 h)		^a	^a	^b
Urinary glucose (mg/mL)	0	^a	0	^b
Urinary uric acid (mg/dL)			^a	^b
Left ventricle mass/tibia length (mg/cm)			^a	^b

Data are presented with , . C: control; CE: control+empagliflozin; HF: high fat; HFE: high fat+empagliflozin. ^a≠C; ^b≠HF. ; one-way ANOVA and posttest Tamhane T2.